Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTX · Real-Time Price · USD
450.91
-4.54 (-1.00%)
At close: Jun 16, 2025, 4:00 PM
448.01
-2.90 (-0.64%)
After-hours: Jun 16, 2025, 7:54 PM EDT
-1.00%
Market Cap 115.79B
Revenue (ttm) 11.10B
Net Income (ttm) -988.90M
Shares Out 256.80M
EPS (ttm) -3.84
PE Ratio n/a
Forward PE 23.90
Dividend n/a
Ex-Dividend Date n/a
Volume 1,029,423
Open 456.38
Previous Close 455.45
Day's Range 448.71 - 457.23
52-Week Range 377.85 - 519.88
Beta 0.42
Analysts Buy
Price Target 512.42 (+13.64%)
Earnings Date Jul 31, 2025

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 1991
Country United States
Stock Exchange NASDAQ
Ticker Symbol VRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $512.42, which is an increase of 13.64% from the latest price.

Price Target
$512.42
(13.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET Company Participants David M. Altshuler - Executive VP & Chief S...

6 days ago - Seeking Alpha

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with ...

10 days ago - Business Wire

Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Cal...

17 days ago - Seeking Alpha

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver...

24 days ago - Seeking Alpha

Vertex to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor...

4 weeks ago - Business Wire

Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft

The Investment Committee give you their top names to watch for the second half.

Other symbols: MSFTPLTRWYNN
5 weeks ago - CNBC Television

Vertex On Track To Significantly Improve Revenue And Earnings By 2030

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain manage...

5 weeks ago - Seeking Alpha

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.

5 weeks ago - Benzinga

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.

The company discloses narrower-than-expected access to its new painkiller.

5 weeks ago - Barrons

Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More

U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following ...

Other symbols: CEGDASH
5 weeks ago - Investopedia

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday.

Other symbols: FNICHR
5 weeks ago - Benzinga

Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)

Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journa...

5 weeks ago - Seeking Alpha

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stua...

6 weeks ago - Seeking Alpha

Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta.

6 weeks ago - Reuters

Vertex Reports First Quarter 2025 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its tota...

6 weeks ago - Business Wire

Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

6 weeks ago - Benzinga

Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the first quarter, after the closing bell on Monday, May 5.

6 weeks ago - Benzinga

Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group

Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!

Other symbols: CMESPGI
6 weeks ago - CNBC Television

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

6 weeks ago - Seeking Alpha

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

6 weeks ago - Seeking Alpha

We're in a pharma stock pickers market, says Kessef's Len Yaffe

Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.

7 weeks ago - CNBC Television

Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom

Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.

Other symbols: ABBVLLY
7 weeks ago - Barrons

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely

Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 1...

2 months ago - Benzinga

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner Internati...

2 months ago - Business Wire

Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike

The Investment Committee give you their top stocks to watch in this volatile markets.

Other symbols: CRWDHOODPANW
2 months ago - CNBC Television